| Name | Title | Contact Details |
|---|
Nuvectra™ is a neuromodulation company committed to helping physicians improve the lives of people with chronic conditions through our medical devices. At Nuvectra, we focus not only on what our devices do, but also on reducing their complexity for clinicians and patients. We are committed to developing products with intelligent innovations and technologies that provide improved outcomes and long-term solutions for our customers. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic intractable pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other indications such as sacral neuromodulation (SNM) for the treatment of overactive bladder and deep brain stimulation (DBS) for the treatment of Parkinson`s Disease. NeuroNexus, a subsidiary owned by Nuvectra, designs, manufactures, and markets leading-edge neural-interface technologies for the neuroscience clinical research market.
Inter Science Institute is a Inglewood, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Health Education Services is a Menlo Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Compugen is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Zai Lab is an innovative, research-based, commercial stage biopharmaceutical company based in China and the U.S. focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Headquartered in Shanghai since our founding in 2014, our experienced team has secured partnerships with leading global biopharma companies, generating a broad and late-stage pipeline of innovative drug candidates. Based on our extensive track record of execution and delivering results, Zai Lab has earned the reputation as a trusted partner of choice for global biopharmaceutical companies seeking to not only access the Chinese market but also find a long-term strategic partner for global clinical development. Through these partnerships, Zai Lab has built the strongest late stage oncology portfolio with global first-in-class and/or best-in-class profile, among innovative Chinese biotech companies. We are further supplementing our pipeline with an in-house discovery effort aiming to produce 1-2 global INDs per year. Zai Lab is rapidly expanding into a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing innovative medicines. To that end, we have built our internal R&D center to advance our discovery pipeline, a strong clinical development and operations team, and our own manufacturing facilities in China. We have also established a highly specialized commercial team to support marketing of our innovative products in China. We believe this integrated approach will provide sustainable competitive advantages for Zai Lab. Zai Lab was successfully listed on the Nasdaq Stock Market in September 2017. Since then, Zai Lab significantly expanded with several offices across China and opened its U.S. headquarters in San Francisco in December 2018. As of December 2019, the Company has a global team of approximately 700 employees.